TY - JOUR
T1 - Heart failure care in low- and middle-income countries
T2 - A systematic review and meta-analysis
AU - Callender, Thomas
AU - Woodward, Mark
AU - Roth, Gregory
AU - Farzadfar, Farshad
AU - Lemarie, Jean Christophe
AU - Gicquel, Stephanie
AU - Atherton, John
AU - Rahimzadeh, Shadi
AU - Ghaziani, Mehdi
AU - Shaikh, Maaz
AU - Bennett, Derrick
AU - Patel, Anushka
AU - Lam, Carolyn S.P.
AU - Sliwa, Karen
AU - Barretto, Antonio
AU - Siswanto, Bambang Budi
AU - Diaz, Alejandro
AU - Herpin, Daniel
AU - Krum, Henry
AU - Eliasz, Thomas
AU - Forbes, Anna
AU - Kiszely, Alastair
AU - Khosla, Rajit
AU - Petrinic, Tatjana
AU - Praveen, Devarsetty
AU - Shrivastava, Roohi
AU - Xin, Du
AU - Macmahon, Stephen
AU - McMurray, John
AU - Rahimi, Kazem
N1 - Funding Information:
CL is funded by a Clinician Scientist Award from the National Medical Research Council of Singapore; receives research grants from Boston scientific, Medtronic, and Vifor Pharma; and serves as a consultant for Bayer and Novartis. JML is employed by the contract research organization Effi-Stat, which receives funding from pharmaceutical and biotechnology companies. In 2009 and 2010 Effi-Stat received financial support from Sanofi-Aventis for providing statistical analysis and programming for the I-Prefer study included in this review (reference ). SG is employed by the contract research organization Effi-Stat, which receives research funding from pharmaceutical and biotechnology companies. AP is a member of the Editorial Board of PLOS Medicine.
Publisher Copyright:
© 2014 Callender et al
PY - 2015
Y1 - 2015
N2 - Heart failure places a significant burden on patients and health systems in high-income countries. However, information about its burden in low- and middle-income countries (LMICs) is scant. We thus set out to review both published and unpublished information on the presentation, causes, management, and outcomes of heart failure in LMICs. Methods and Findings: Medline, Embase, Global Health Database, and World Health Organization regional databases were searched for studies from LMICs published between 1 January 1995 and 30 March 2014. Additional unpublished data were requested from investigators and international heart failure experts. We identified 42 studies that provided relevant information on acute hospital care (25 LMICs; 232,550 patients) and 11 studies on the management of chronic heart failure in primary care or outpatient settings (14 LMICs; 5,358 patients). The mean age of patients studied ranged from 42 y in Cameroon and Ghana to 75 y in Argentina, and mean age in studies largely correlated with the human development index of the country in which they were conducted (r= 0.71, p,0.001). Overall, ischaemic heart disease was the main reported cause of heart failure in all regions except Africa and the Americas, where hypertension was predominant. Taking both those managed acutely in hospital and those in nonacute outpatient or community settings together, 57% (95% confidence interval [CI]: 49%–64%) of patients were treated with angiotensin-converting enzyme inhibitors, 34% (95% CI: 28%–41%) with beta-blockers, and 32% (95% CI: 25%–39%) with mineralocorticoid receptor antagonists. Mean inpatient stay was 10 d, ranging from 3 d in India to 23 d in China. Acute heart failure accounted for 2.2% (range: 0.3%–7.7%) of total hospital admissions, and mean in-hospitalmortalitywas 8% (95% CI: 6%–10%). There was substantial variation between studies (p,0.001 across all variables), and most data were from urban tertiary referral centres. Only one population-based study assessing incidence and/or prevalence of heart failure was identified. Conclusions: The presentation, underlying causes, management, and outcomes of heart failure vary substantially across LMICs. On average, the use of evidence-based medications tends to be suboptimal. Better strategies for heart failure surveillance and management in LMICs are needed.
AB - Heart failure places a significant burden on patients and health systems in high-income countries. However, information about its burden in low- and middle-income countries (LMICs) is scant. We thus set out to review both published and unpublished information on the presentation, causes, management, and outcomes of heart failure in LMICs. Methods and Findings: Medline, Embase, Global Health Database, and World Health Organization regional databases were searched for studies from LMICs published between 1 January 1995 and 30 March 2014. Additional unpublished data were requested from investigators and international heart failure experts. We identified 42 studies that provided relevant information on acute hospital care (25 LMICs; 232,550 patients) and 11 studies on the management of chronic heart failure in primary care or outpatient settings (14 LMICs; 5,358 patients). The mean age of patients studied ranged from 42 y in Cameroon and Ghana to 75 y in Argentina, and mean age in studies largely correlated with the human development index of the country in which they were conducted (r= 0.71, p,0.001). Overall, ischaemic heart disease was the main reported cause of heart failure in all regions except Africa and the Americas, where hypertension was predominant. Taking both those managed acutely in hospital and those in nonacute outpatient or community settings together, 57% (95% confidence interval [CI]: 49%–64%) of patients were treated with angiotensin-converting enzyme inhibitors, 34% (95% CI: 28%–41%) with beta-blockers, and 32% (95% CI: 25%–39%) with mineralocorticoid receptor antagonists. Mean inpatient stay was 10 d, ranging from 3 d in India to 23 d in China. Acute heart failure accounted for 2.2% (range: 0.3%–7.7%) of total hospital admissions, and mean in-hospitalmortalitywas 8% (95% CI: 6%–10%). There was substantial variation between studies (p,0.001 across all variables), and most data were from urban tertiary referral centres. Only one population-based study assessing incidence and/or prevalence of heart failure was identified. Conclusions: The presentation, underlying causes, management, and outcomes of heart failure vary substantially across LMICs. On average, the use of evidence-based medications tends to be suboptimal. Better strategies for heart failure surveillance and management in LMICs are needed.
UR - http://www.scopus.com/inward/record.url?scp=84936146850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84936146850&partnerID=8YFLogxK
U2 - 10.1371/journal.pmed.1001699
DO - 10.1371/journal.pmed.1001699
M3 - Article
C2 - 25117081
AN - SCOPUS:84936146850
SN - 1549-1277
VL - 11
JO - PLoS Medicine
JF - PLoS Medicine
IS - 8
M1 - A011
ER -